ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 2419 • ACR Convergence 2024

    Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data

    Richard Furie1, Mawuena Binka2, Gelareh Atefi3, Stephanie Y. Chen4 and Bo Ding5, 1Northwell Health, Manhasset, NY, 2BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 3AstraZeneca, Media, PA, 4BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: SLE is an autoimmune disease with diverse manifestations and progression patterns that, via disease activity and effects of standard therapy, imposes a significant burden…
  • Abstract Number: 0359 • ACR Convergence 2024

    SpA Disk©: A New Tool to Monitor the QoL of Spondyloarthritis Patients

    Roba Ghossan1, OLIVIER FOGEL2, Cécile Gaujoux-Viala3, anthony SABER4, Cedric Lukas5 and Corinne MICELI6, and SpA Disk Group, 1COCHIN HOSPITAL, PARIS, France, 2AP-HP, Paris, France, 3CHU Nîmes, Nïmes, Languedoc-Roussillon, France, 4Sorbonne Paris Nord Université, Paris, France, 5Rheumatology department, CHU Montpellier, Montpellier, France, 6Université de Paris Cité, APHP, Paris, France

    Background/Purpose: Spondyloarthritis (SpA) significantly affects patients' quality of life (QoL). Current tools in routine medical practice primarily focus on assessing disease activity, neglecting the broader…
  • Abstract Number: 0600 • ACR Convergence 2024

    Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies

    Laure Gossec1, Dafna Gladman2, Laura Coates3, Maarten de Wit4, Barbara Ink5, Rajan Bajracharya5, Jason Coarse6, Jérémy Lambert7 and Ana-Maria Orbai8, 1Sorbonne Université, Paris, France, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 4Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, 5UCB Pharma, Slough, United Kingdom, 6UCB Pharma, Morrisville, NC, 7UCB Pharma, Colombes, France, 8Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A, has demonstrated sustained reductions in disease impact of PsA, assessed…
  • Abstract Number: 1028 • ACR Convergence 2024

    Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

    Julia Harris1, Nancy Pan2, Catherine Bingham3, Sheetal Vora4, Cagri Yildirim-Toruner5, Kerry Ferraro6, Erik Friedrichsen7, Michelle Batthish8, Jon Burnham9, Danielle Fair10, Suhas Ganguli11, Mileka Gilbert12, Beth Gottlieb13, Olha Halyabar14, Melissa Hazen15, Tzielan Lee16, Daniel Lovell17, Melissa Mannion18, Edward Oberle19, Linda Ray20, Michael Shishov21, Mary Toth22 and Esi Morgan23, 1Children's Mercy Kansas City, Overland Park, KS, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Penn State Children’s Hospital, Hershey, 4Atrium Health Levine Children's Hospital, Charlotte, NC, 5Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, 6JIA parent and CHOP volunteer, Lower Gwynedd, PA, 7Seattle Children's Hospital, Seattle, 8McMaster Children's Hospital, Hamilton, ON, Canada, 9Children's Hospital of Philadelphia, Philadelphia, PA, 10Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, 11Hackensack University Medical Center, Hackensack, 12Medical University of South Carolina, Charleston, SC, 13Cohen Children's Medical Center, Lake Success, NY, 14Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 15Boston Children's Hospital, Boston, MA, 16Stanford University School of Medicine, Palo Alto, CA, 17Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 18University of Alabama at Birmingham, Birmingham, AL, 19Nationwide Children's Hospital, Columbus, OH, 20University of Mississippi Medical Center, Jackson, MS, 21Phoenix Children's Hospital, Phoenix, AZ, 22Nemours Foundation, Orlando, FL, 23Seattle Children's Hospital, Seattle, WA

    Background/Purpose: As healthcare moves towards more patient-centered care, it is increasingly important to integrate patients’ opinions into clinical assessments and decision-making. The Pediatric Rheumatology Care…
  • Abstract Number: 1253 • ACR Convergence 2024

    Patterns of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus with or Without Concurrent Fibromyalgia

    Heather Gold1, Yi Li1, Rebecca Anthopolos1, Peter Izmirly2, Jill Buyon1, Mala Masson3, Brooke Cohen1, Kamil Barbour4, Amit Saxena5, H Michael Belmont5, Chung-E Tseng6 and Kelly Corbitt7, 1NYU Grossman School of Medicine, New York, NY, 2New York University Grossman School of Medicine, New York, NY, 3NYU Langone Medical Center- Division of Rheumatology, New York, NY, 4CDC, Alpharetta, GA, 5NYU School of Medicine, New York, NY, 6NYU Langone Health, Flushing, NY, 7University of Miami Miller School of Medicine, El Portal, FL

    Background/Purpose: Patients with SLE often have concomitant FM or symptoms similar to FM, including chronic pain, fatigue, sleep disturbance, and/or depression, potentially distinct from immune-mediated…
  • Abstract Number: 1380 • ACR Convergence 2024

    Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib

    Manish Jain1, Arthur Kavanaugh2, Angela Crowley3, Avani Joshi4, Patrick Zueger5, Diane Caballero6, Andrew Garrison6 and Peter C. Taylor7, 1Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, 2University of California San Diego, La Jolla, CA, 3Illinois Bone and Joint Institute, Hinsdale Orthopaedics, Hinsdale, IL, 4AbbVie, North Chicago, IL, 5AbbVie Inc, North Chicago, IL, 6AbbVie Inc., North Chicago, IL, 7University of Oxford, Oxford, United Kingdom

    Background/Purpose: Pain is a crucial symptom for patients with RA; early and effective treatment can help alleviate it.1 In this post hoc analysis, we investigated…
  • Abstract Number: 1743 • ACR Convergence 2024

    What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?

    Jing Zhao1, Urbano Sbarigia2, Jackie Kwong1, Chinmayi Naik3, Federico Zazzetti4, Nancy Shadick3 and Michael Weinblatt5, 1Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, 2Johnson & Johnson Innovative Medicine, Brussels, Belgium, 3Brigham and Women’s Hospital, Boston, MA, 4Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 5Brigham and Women's Hospital/ Harvard Medical School, Waban, MA

    Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
  • Abstract Number: 2168 • ACR Convergence 2024

    Two Year Data on Quality of Life, Pain and Mobility Scores After Rituximab Treatment in the Preclinical Phase of Rheumatoid Arthritis

    Giulia Frazzei1, Sophie Cramer1, Robert Landewé2, Karen Maijer3, Danielle Gerlag4, Paul Tak, MD PhD5, Niek De Vries6, Lisa van Baarsen6, Ronald Van Vollenhoven7 and Sander Tas8, 1Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, 2Amsterdam University Medical Center, Meerssen, Netherlands, 3Tergooi Hospital, Hilversum, Amsterdam, Netherlands, 4UCB, Cambridge, United Kingdom, 5Candel Therapeutics, Cambridge, United Kingdom, 6Amsterdam UMC, Amsterdam, Netherlands, 7Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Over the past 10 years, several trials have investigated prevention of rheumatoid arthritis (RA) by disease modifying antirheumatic drug (DMARD) therapies. Early treatment of…
  • Abstract Number: 2448 • ACR Convergence 2024

    Content Validity and Sensitivity to Change of ScleroID Through the Natural History of Scleroderma. a Validated Tool to Measure the Impact of SSc on How Patients Feel and Function

    Seda Colak1, Stefano Di Donato2, Riccardo Bixio3, Lesley-Anne Bissell4, Theresa Barnes5, Christopher Denton6, Muhammad Nisar7 and Francesco Del Galdo8, 1Gulhane Training and Research Hospital, Ankara, Turkey, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 3University of Verona, Verona, Verona, Italy, 4Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5Countess of Chester, Liverpool, United Kingdom, 6University College London, Northwood, United Kingdom, 7Bedfordshire hospitals, BEDFORD, United Kingdom, 8University of Leeds, Leeds, United Kingdom

    Background/Purpose: Multiple patient-reported outcomes (PROs) have been utilized to capture the burden of Systemic Sclerosis (SSc), including the Health Assessment Questionnaire Disability Index (HAQ-DI), Cochin…
  • Abstract Number: 0362 • ACR Convergence 2024

    Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus

    Anna Deck1, Paula Caras2, Kiran Singh3, Monique Gore-Massy4, Faye Chiu5, Sara Folta6 and Shanthini Kasturi3, 1Tufts University School of Medicine, Portland, ME, 2Tufts University School of Medicine, Boston, MA, 3Tufts Medical Center, Boston, MA, 4Lupus Foundation of America, New Jersey, 5N/A, New York City, NY, 6Tufts University/Tufts University Friedman School of Nutrition, Boston, MA

    Background/Purpose: Fatigue is the single most prevalent symptom of systemic lupus erythematous (SLE), affecting 80-90% of patients, and is often refractory to pharmacologic therapy. Non-pharmacologic…
  • Abstract Number: 0601 • ACR Convergence 2024

    Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib

    Peter C. Taylor1, Lihi Eder2, Yael Klionsky3, Fabian Proft4, Thomas Iyile5, Erin Mancl6, Priscila Magalhaes Reis Nakasato7, Xiaolan Ye8, Limei Zhou6 and Philip Mease9, 1University of Oxford, Oxford, United Kingdom, 2University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 3Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 4Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5AbbVie Inc., hyattsville, MD, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., Randolph, NJ, 8AbbVie Inc., Mettawa, IL, 9Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Severe musculoskeletal manifestations of PsA, particularly joint pain, can result in reduced physical function, decreased quality of life, and progressive and irreversible joint damage.1,2…
  • Abstract Number: 1040 • ACR Convergence 2024

    Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics

    Jasvinder Singh1, Larry Hearld2, Walter Chatham3, Sonali Narain4, Narender Annapureddy5, Diane Kamen6, Kimberly Trotter7, vikas Majithia8, Cathy Lee Ching9, Zineb Aouhab10, Swamy Venuturupalli11, Daniel Wallace12, rosalind Ramsey-Goldman13, Alfred Kim14, Maureen McMahon15, S. Sam Lim16, Kalpana Bhairavarasu17, Alexa Meara18 and Kenneth Kalunian19, 1Baylor College of Medicine, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV, 4Northwell Health, Great Neck, NY, 5Vanderbilt University Medical Center, Nashville, TN, 6Medical University of South Carolina, Charleston, SC, 7University of Chicago, Chicago, IL, 8University of Missisippi Medical Center (UMC), Jackson, MS, 9UMMC, Jackson, MS, 10Loyola University Medical Center, Oak Brook, IL, 11Attune Health, Beverly Hills, CA, 12Cedars Sinai Medical Center, Studio City, CA, 13Northwestern University, Chicago, IL, 14Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 15UCLA David Geffen School of Medicine, Los Angeles, CA, 16Emory University, Atlanta, GA, 17Baylor College of Medicine, Sugar Land, TX, 18The Ohio State University Wexner Medical Center, COLUMBUS, OH, 19University of California San Diego, La Jolla, CA

    Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.Methods: We provided self-administered…
  • Abstract Number: 1254 • ACR Convergence 2024

    The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice

    Robert Spiera1, Paul Dolin2, Anat Shavit2, Jennifer Rowell3, Chris Edmonds4, Josefine Persson5, Danuta Kielar6, Daniel Mascia7, James Siddall7, Tia Pennant7, Fritha Hennessy7 and Stephanie Y. Chen8, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Market Access and Pricing, AstraZeneca, Gothenburg, Sweden, 6Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, 7Adelphi Real World, Bollington, United Kingdom, 8BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody-associated vasculitis that confers significant disease burden. This real-world study described the impact of…
  • Abstract Number: 1387 • ACR Convergence 2024

    Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study

    Andrey Karateev1, Sofia Kuzkina2, Galym Togizbayev3, Elena Polishuk1, Ekaterina Filatova1, Vera Amirdzhanova1, Victoria Khlaboshchina1, Natalia Lapkina4, Andrey Baranov4 and Alexander Lila5, 1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 2R-Pharm, Moscow, Russia, 3Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, 4Yaroslavl State Medical University, Yaroslavl, Russia, 5Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

    Background/Purpose: To evaluate efficacy and safety of olokizumab (interleukin-6 inhibitor) in RA patients with special attention to chronic pain and a signs of central sensitization.Methods:…
  • Abstract Number: 1943 • ACR Convergence 2024

    Virtual Rheumatology in the Real World: Use of Telemonitoring to Optimize the Management of Patients with Rheumatoid Arthritis

    Maria Di Cicco1, Elisa Verduci1, Marina Muscarà1, Laura Belloli1, Antonella Adinolfi1, Cinzia Casu1, Davide Filippini1, Federica Filippini2, Maria Chiara Gerardi1, Martina Schettino1, Nicola Ughi3 and Oscar Massimiliano Epis1, 1Niguarda Hospital, Milan, Milan, Italy, 2Bicocca University, Milan, Italy, 3Niguarda Hospital, Milan, Mila, Italy

    Background/Purpose: The burden of chronic musculoskeletal disease is increasing worldwide, with a high demand for innovative approaches to deliver effective, feasible and cost-effective access to…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 43
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology